125 related articles for article (PubMed ID: 3339358)
1. Muscarinic cholinergic receptor subtypes in hippocampus in human cognitive disorders.
Smith CJ; Perry EK; Perry RH; Candy JM; Johnson M; Bonham JR; Dick DJ; Fairbairn A; Blessed G; Birdsall NJ
J Neurochem; 1988 Mar; 50(3):847-56. PubMed ID: 3339358
[TBL] [Abstract][Full Text] [Related]
2. Cholinergic receptors in cognitive disorders.
Perry EK; Perry RH; Smith CJ; Purohit D; Bonham J; Dick DJ; Candy JM; Edwardson JA; Fairbairn A
Can J Neurol Sci; 1986 Nov; 13(4 Suppl):521-7. PubMed ID: 3791066
[TBL] [Abstract][Full Text] [Related]
3. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types.
Perry EK; Smith CJ; Court JA; Perry RH
J Neural Transm Park Dis Dement Sect; 1990; 2(3):149-58. PubMed ID: 2175197
[TBL] [Abstract][Full Text] [Related]
4. Parallel postnatal development of choline acetyltransferase activity and muscarinic acetylcholine receptors in the rat olfactory bulb.
Large TH; Lambert MP; Gremillion MA; Klein WL
J Neurochem; 1986 Mar; 46(3):671-80. PubMed ID: 3754001
[TBL] [Abstract][Full Text] [Related]
5. Regional distribution of muscarinic and nicotinic cholinergic receptor binding activities in the human brain.
Perry EK; Smith CJ; Perry RH; Whitford C; Johnson M; Birdsall NJ
J Chem Neuroanat; 1989; 2(4):189-99. PubMed ID: 2597358
[TBL] [Abstract][Full Text] [Related]
6. Cortical muscarinic receptor subtypes and Alzheimer's disease.
Caulfield MP; Straughan DW; Cross AJ; Crow T; Birdsall NJ
Lancet; 1982 Dec; 2(8310):1277. PubMed ID: 6128572
[No Abstract] [Full Text] [Related]
7. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies.
Flynn DD; Weinstein DA; Mash DC
Ann Neurol; 1991 Mar; 29(3):256-62. PubMed ID: 2042942
[TBL] [Abstract][Full Text] [Related]
8. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease.
Araujo DM; Lapchak PA; Robitaille Y; Gauthier S; Quirion R
J Neurochem; 1988 Jun; 50(6):1914-23. PubMed ID: 3373218
[TBL] [Abstract][Full Text] [Related]
9. Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia.
Ruberg M; Ploska A; Javoy-Agid F; Agid Y
Brain Res; 1982 Jan; 232(1):129-39. PubMed ID: 7055689
[TBL] [Abstract][Full Text] [Related]
10. Regional distribution of M1, M2 and non-M1, non-M2 subtypes of muscarinic binding sites in rat brain.
Ehlert FJ; Tran LP
J Pharmacol Exp Ther; 1990 Dec; 255(3):1148-57. PubMed ID: 2262898
[TBL] [Abstract][Full Text] [Related]
11. Short-term desensitization of muscarinic cholinergic receptors in mouse neuroblastoma cells: selective loss of agonist low-affinity and pirenzepine high-affinity binding sites.
Cioffi CL; el-Fakahany EE
J Pharmacol Exp Ther; 1986 Sep; 238(3):916-23. PubMed ID: 3018226
[TBL] [Abstract][Full Text] [Related]
12. Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer's disease: an autoradiographic study.
Probst A; Cortés R; Ulrich J; Palacios JM
Brain Res; 1988 May; 450(1-2):190-201. PubMed ID: 3401711
[TBL] [Abstract][Full Text] [Related]
13. Muscarinic cholinergic receptor subtypes in the human brain. II. Quantitative autoradiographic studies.
Cortés R; Probst A; Tobler HJ; Palacios JM
Brain Res; 1986 Jan; 362(2):239-53. PubMed ID: 3753655
[TBL] [Abstract][Full Text] [Related]
14. Multiple binding affinities of N-methylscopolamine to brain muscarinic acetylcholine receptors: differentiation from M1 and M2 receptor subtypes.
el-Fakahany EE; Ramkumar V; Lai WS
J Pharmacol Exp Ther; 1986 Aug; 238(2):554-63. PubMed ID: 3755473
[TBL] [Abstract][Full Text] [Related]
15. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease.
Lange KW; Wells FR; Jenner P; Marsden CD
J Neurochem; 1993 Jan; 60(1):197-203. PubMed ID: 8417140
[TBL] [Abstract][Full Text] [Related]
16. Increases in muscarinic stimulated hydrolysis of inositol phospholipids in rat hippocampus following cholinergic deafferentation are not parallelled by alterations in cholinergic receptor density.
Smith CJ; Court JA; Keith AB; Perry EK
Brain Res; 1989 Apr; 485(2):317-24. PubMed ID: 2720416
[TBL] [Abstract][Full Text] [Related]
17. Brain muscarinic receptor subtypes are differently affected in Alzheimer's disease and Parkinson's disease.
Rinne JO; Lönnberg P; Marjamäki P; Rinne UK
Brain Res; 1989 Apr; 483(2):402-6. PubMed ID: 2706531
[TBL] [Abstract][Full Text] [Related]
18. [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation].
Dubois B; Hauw JJ; Ruberg M; Serdaru M; Javoy-Agid F; Agid Y
Rev Neurol (Paris); 1985; 141(3):184-93. PubMed ID: 4001706
[TBL] [Abstract][Full Text] [Related]
19. Perinatal low-level lead exposure and the septo-hippocampal cholinergic system: selective reduction of muscarinic receptors and cholineacetyltransferase in the rat septum.
Bielarczyk H; Tomsig JL; Suszkiw JB
Brain Res; 1994 Apr; 643(1-2):211-7. PubMed ID: 8032916
[TBL] [Abstract][Full Text] [Related]
20. Differences between rat dorsal and ventral hippocampus in muscarinic receptor agonist binding and interaction with phospholipase C.
Garcia Ruiz AJ; Zambelli M; La Porta C; Ladinsky H; Consolo S
Eur J Pharmacol; 1993 Jan; 244(2):125-31. PubMed ID: 8432309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
